The FENhance 1 and 2 trials involved 1,497 adults with RMS. Credit: New Africa / Shutterstock.com. Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s ...
The US Food and Drug Administration (FDA) has released the clinical hold on a second trial evaluating Intellia Therapeutics’ transthyretin amyloidosis with cardiomyopathy (ATTR-CM) gene therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results